Phase Ib data

Ascentage Pharma’s olverembatinib demonstrated promising Phase Ib results in SDH-deficient GIST, with an ORR of 23.1% and CBR of 84.6%. Median PFS reached 25.7 months. Translational analyses revealed CD36 overexpression and dysregulated lipid metabolism. Olverembatinib reduced CD36 and lipid uptake while inhibiting HIF, FGFR, and VEGFR pathways. It holds Breakthrough Therapy Designation in China. A global Phase III trial (POLARIS-3, NCT06640361) is ongoing.